Tech Company Financing Transactions

Xanthus Pharmaceuticals Funding Round

CDIB Bioscience, GeneChem and GIMV participated in a $25 million Series B funding round for Xanthus Pharmaceuticals. The funding round was announced on 12/1/2006.

Transaction Overview

Announced On
12/1/2006
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Proceeds Purpose
Richard T. Dean, Ph.D., Xanthus' Chief Executive Officer said, "With this financing, we believe Xanthus is wellpositioned for the continued development of our pipeline of five oncology products."

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
300 Technology Square 5th Floor
Cambridge, MA 02139
USA
Email Address
Overview
Xanthus is a biopharmaceutical company focused on the discovery, development, acquisition and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Profile
Xanthus Pharmaceuticals LinkedIn Company Profile
Social Media
Xanthus Pharmaceuticals Company Twitter Account
Company News
Xanthus Pharmaceuticals News
Facebook
Xanthus Pharmaceuticals on Facebook
YouTube
Xanthus Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Richard Dean
  Richard Dean LinkedIn Profile  Richard Dean Twitter Account  Richard Dean News  Richard Dean on Facebook
Chief Financial Officer
Robert Boisjoli
  Robert Boisjoli LinkedIn Profile  Robert Boisjoli Twitter Account  Robert Boisjoli News  Robert Boisjoli on Facebook
Chief Medical Officer
Robert Capizzi
  Robert Capizzi LinkedIn Profile  Robert Capizzi Twitter Account  Robert Capizzi News  Robert Capizzi on Facebook
Chief Operating Officer
Michael Boss
  Michael Boss LinkedIn Profile  Michael Boss Twitter Account  Michael Boss News  Michael Boss on Facebook
Chief Scientific Officer
Alfred Ajami
  Alfred Ajami LinkedIn Profile  Alfred Ajami Twitter Account  Alfred Ajami News  Alfred Ajami on Facebook
Vice President
John Lister-James
  John Lister-James LinkedIn Profile  John Lister-James Twitter Account  John Lister-James News  John Lister-James on Facebook
VP - Regulatory Affairs
Kris Piper
  Kris Piper LinkedIn Profile  Kris Piper Twitter Account  Kris Piper News  Kris Piper on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/1/2006: BitTorrent venture capital transaction
Next: 12/1/2006: NextHop Technologies venture capital transaction

 

Share this article

 


Where The Data Comes From

We document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary